Accordingly, in vitro and in vivo re-expression of SST2 in human pancreatic cancer cell lines through SST2 cDNA transfection (Delesque et al., 1997; Guillermet et al., 2003; Laval et al., 2014) and through in vivo SST2 gene transfer in mouse models (Vernejoul et al., 2002) and in a first-in-man phase I clinical trial (Buscail et al., 2015), respectively, demonstrated promising oncosuppressive activity in advanced pancreatic cancer. This evidence concerns the gene SSTR2 and familial pancreatic carcinoma.